# YARROW BIOSCIENCE, INC. (YARW) · Edgar & Edgarette company card

> Yarrow Bioscience (YARW) grew revenue 13.8% in FY2025 to $1 million, operating margin -5219% against a -3.8% median for pharmaceutical preparations, equity 92.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1566044 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/YARW) · [JSON](https://www.pops4.com/boards/company/YARW.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $570,000 |
| Revenue growth, 1 year | 13.8% |
| Revenue growth per year | -11.5% |
| Operating margin | -5219.1% (prior year -8710.0%) |
| Net margin | -4646.1% |
| Operating cash flow | −$33M |
| Capital spending | $0 |
| Free cash flow | −$33M |
| Cash | $24M |
| Long-term debt | $0 |
| Total assets | $30M |
| Total equity | $28M |
| Equity ÷ assets | 92.1% |
| Return on equity | -95.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -70.34 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$33.1M in FY2025); operating loss: a margin of -5219.1% in FY2025; revenue is hard to predict: its 80% range is ±59%

## Edgarette's reading

Exposure: revenue $570K (FY2025), total debt $0K. Experience: revenue up 13.8% on the year, down 11.5% a year over 4 years; operating margin -5219.1%, up from -8710.0%. Soundness: equity 92.1% of assets, return on equity -95.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $314K and $1.2M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $286K to $1.3M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -5219.1% against a -3.8% median; growth 13.8% against 13.7%.

Range logged 2026-09-29, receipt 4e280628447badbb, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-03-11 ([filing](https://www.sec.gov/Archives/edgar/data/1566044/000110465926026439/0001104659-26-026439-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-07-28 ([filing](https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm))

## Recent filings

- 8-K · filed 2026-09-14 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1566044/000110465926107485/0001104659-26-107485-index.htm)
- 8-K · filed 2026-09-10 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1566044/000110465926106699/0001104659-26-106699-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000010/0001566044-26-000010-index.htm)
- 8-K · filed 2026-07-30 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1566044/000110465926088662/0001104659-26-088662-index.htm)
- 8-K · filed 2026-07-28 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.02 Results of Operations and Financial Condition; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modifications to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.05 Amendments to the Code of Ethics; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1566044/000110465926087601/0001104659-26-087601-index.htm)
- 8-K · filed 2026-07-21 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1566044/000110465926085235/0001104659-26-085235-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001566044.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1566044

## Cite

POPS4, Edgar & Edgarette: YARROW BIOSCIENCE, INC. (YARW) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/YARW. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.